Brind.
  1. Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation.

Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.

6 reports, 4 independent Updated Aug 5
Gone quiet Reached 3 outlets in its first 24 hours
Reports
6
Developments
4
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.

Who's involved

What this event is mainly about
NateraNeoGenomicsHoffmann-La RocheNRG Oncology

How it developed

Newest first. Tap a step to see who reported it.
  1. Natera submitted its application for the Signatera test and reported market activity on the exchange.1 source
  2. Natera's Signatera test advances to Phase III trial amidst patent litigation.1 source
  3. Natera's Signatera test is being utilized in the ARCHER trial involving Genentech and NRG Oncology.1 source
  4. Natera test incorporated into NRG Oncology Phase III trial, enrolling in US and Canada.1 source

Keep exploring

Part of

Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • finanznachrichten.de
  • StockStoryWhy Natera (NTRA) Stock Is Down Today Shares of genetic testing company Natera (NASDAQ:NTRA). fell 0.9% in the morning session after the company announced an unfavorable court ruling in its ongoing p
  • Medical Device NetworkNatera’s Signatera test to be used in Phase III bladder cancer trial US-based clinical genetic testing company Natera said that its Signatera test will be utilised in the newly activated ARCHER trial
  • Business WireCourt Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera – NeoGenomics wins summary judgment in patent infringement lawsuit against Natera; Court rules Natera’s patents are invalid f
  • StockStoryWhy Natera (NTRA) Stock Is Up Today Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 3% in the afternoon session after the company announced its Signatera molecular residual disease tes
  • Business WireSignatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurre